What's new? Log in Free sign up

BioVaxys Technology (BVAXF)

Company Profile

Company profile

Ticker

BVAXF

Exchange

Website

www.biovaxys.com

CEO

Mr. James Christopher Passin

Incorporated

British Columbia, Canada

Location

Ontario, Canada

Fiscal year end

Sector

Health Technology > Biotechnology

SEC CIK

BVAXF stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

$173.07 k in equity / options / securities to be acquired, sold $52.32 k, 1 investor

$248.54K in equity / options, sold $248.54K, 8 investors

Latest ownership filings

No filings

Press releases

From Benzinga Pro

BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*

VANCOUVER, BC, Jan. 16, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") highlights the potential for its DPX™ non-systemic immune

BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*

VANCOUVER, BC, Jan. 16, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") highlights the potential for its DPX™ non-systemic immune educating

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth

BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025

BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.